Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials-Reference-Cited by-同舟云学术

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

Published:2016-12-19 Issue:3 Volume:19 Page:336-347
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Bettge Karolin¹,Kahle Melanie¹,Abd El Aziz Mirna S.¹,Meier Juris J.¹,Nauck Michael A.¹

Affiliation:

1. Division of Diabetology, Medical Department I, St. Josef Hospital; Ruhr-University Bochum; Bochum Germany

Funder

Amylin Pharmaceuticals

Eli Lilly and Company

Boehringer Ingelheim

GlaxoSmithKline

Novartis Pharma

Novo Nordisk

Novartis

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12824/fullpdf

Reference53 articles.

1. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

2. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes Obes Metab,2016

3. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes;DeFronzo;Diabetes care,2005

4. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus;Meier;Nat Rev Endocrinol,2012

5. Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M);Ahren;Diabetes Care,2013

Cited by 220 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist;Gynecologic Oncology;2024-11

2. The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension;Clinical Hypertension;2024-09-01

3. Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Exploring Their Impact on Diabetes, Obesity, and Cardiovascular Health Through a Comprehensive Literature Review;Cureus;2024-09-01

4. Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice;Endocrine;2024-08-30

5. A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy;Diabetes, Obesity and Metabolism;2024-08-27